You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: VELUM INC Topic: 300
PROJECT SUMMARY! Peptide therapeutics combine high potency and selectivityand engender fewer side effects than traditional small moleculesThis has fueled interest in peptides filling the gap between `biologicsandaposand small molecules as compounds that have key desired properties from both the other classesThere are however some challengesthe major one being susceptibility to enzyme catalyzed hyd ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: Rimedion, Inc. Topic: NHLBI
DESCRIPTIONprovided by applicantIn this Phase II STTR application Rimedion seeks to commercialize a novel treatment for patients suffering from Fanconi anemia and request funding for a Phase I II clinical trialThe product will utilize a HIVbased lentiviral vector expressin the Fanconi anemia A proteinThe strong scientific support for this approached is strengthened by a successful Phase I STTRThe ...STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: ZMK Medical Technologies, Inc. Topic: 102
This Phase II proposal is a continuation of our successful Phase I grant whose overarching goal is to develop a more robust and accurate method for the deformable fusion of pre operative magnetic resonance images MRI and intra procedure trans rectal ultrasound TRUS images to guide prostate biopsy Prostate cancer is a major cause of death in the U S and biopsy is the gold standard for its dia ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: ARRHYTHMOTECH Topic: NIDA
DESCRIPTION provided by applicant The objective of this Phase II STTR grant application is to continue the R Randamp D efforts initiated in Phase I The long term objective for Arrhythmotech is to develop and market an instrument for the simultaneous recording of sympathetic nerve activity SNA and electrocardiogram ECG using electrodes on the skin This method neuECG was discovered in Dr ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: FieldLine Inc. Topic: 101
Abstract During Phase Iwe will test the feasibility of developing a magnetographic camera technology as a new tool in neuroscience to facilitate the detailed analysis of electrical currents in diverse neuronal circuitsInstead of photographic imagesthe camera will produce single shot images of the magnetic fields from in vivo samples of interestsuch as a patch of the grey matter in the cerebral cor ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: INTELON OPTICS, INC. Topic: N
ABSTRACT The overall goal of this STTR project is to commercialize a novel optical eye scanner device capable of measuring the biomechanical properties of tissues via Brillouin light scatteringThe Brillouin technology invented in the co PI s lab has shown broad potential for improving the diagnosis and treatment of vision disordersClinical data obtained with current laboratory systems revealed cor ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: FasCure Therapeutics LLC Topic: 102
DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: Cyteir Therapeutics, Inc. Topic: NCI
DESCRIPTION provided by applicant Genomic instability is a hallmark of cancer and represents a targetable vulnerability yet is underdeveloped as a therapeutic area The central goal of this Phase program is to complete the early preclinical development of a new class of new cancer therapeutics that uniquely target RAD delivering effective cancer cell selective therapy in subsets of bioma ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: PAUL H BROOKES PUBLISHING CO., INC. Topic: Y
DESCRIPTIONprovided by applicantEffective early intervention depends on reliable screening of risk for communication impairments as soon as possibleEstablished infant communication risk factors include poor attentiongesturessocial connectednessexploratory playand speechAlthough these risk factors can be detected bymosand reliably predict later language and social disordersattempts to detect simila ...STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: CytoInformatics LLC Topic: NIA
DESCRIPTION provided by applicant There is growing awareness that weakness of muscle is a significant biomedical health issue associated with many different chronic diseases and aging There are a variety of different diseases that affect muscle including muscular dystrophy fibromyalgia cerebral palsy amyotrophic lateral sclerosis and myasthenia gravis each of which carries its own uniqu ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health